Area of research
Infectious Diseases · Emergency Medicine
Research interest
Research interests include Medicine, Pharmacokinetics, Dolutegravir, Dosing, Cmax, and Pregnancy.
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years
Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL Trial
First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
Advancing the prevention and treatment of HIV in children: priorities for research and development
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
UCL Discovery (University College London) 2021cited by 103position: middle
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial
Suboptimal Dosing of Fluconazole in Critically Ill Patients: Time To Rethink Dosing
Enhanced and Timely Investigation of ARVs for Use in Pregnant Women
Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list
Etravirine Pharmacokinetics in HIV-Infected Pregnant Women
Raltegravir in HIV-1–Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy
Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women*
The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women